Cancer Family
Melanocytic Neoplasm
CI-CAN-00000026Explore in graph →
Non-malignant610 active trials13 approved drugs233 evidence items
- NCIt
- C7058
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000026Explore in graph →
Clinical trials
3,258 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06946225 | ACTengine® IMA203 Combined With mRNA-4203 | recruiting | Phase 1 | 15 | Immatics US, Inc.INDUSTRY | 1 | Jan 8, 2026 | clinicaltrials |
| NCT07161310 | Urolithin A in Patients With Previously Untreated Solid Tumors Receiving Immune Checkpoint Inhibitors(MitoCancer) | recruiting | N/A | 45 | Goethe UniversityOTHER | 1 | Jan 8, 2026 | clinicaltrials |
| NCT05544929 |
| A Study of Safety and Efficacy of KFA115 Alone and in Combo With Pembrolizumab in Patients With Select Advanced Cancers |
| active not recruiting |
| Phase 1 |
| 126 |
| Novartis PharmaceuticalsINDUSTRY |
| 12 |
| Jan 6, 2026 |
| clinicaltrials |
| NCT07320222 | CARE-Melanoma Trial(CARE-Melanoma) | not yet recruiting | Phase 1 | 30 | McMaster UniversityOTHER | 0 | Jan 6, 2026 | clinicaltrials |
| NCT03929029 | Neoantigen Vaccine Plus Locally Administered Ipilimumab and Systemic Nivolumab in Advanced Melanoma | active not recruiting | Phase 1 | 11 | Dana-Farber Cancer InstituteOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT05428007 | Interleukin-6 Receptor Inhibitor Sarilumab in Combination With Ipilimumab, Nivolumab and Relatlimab in Patients With Unresectable Stage III or Stage IV Melanoma | recruiting | Phase 2 | 105 | NYU Langone HealthOTHER | 1 | Jan 5, 2026 | clinicaltrials |
| NCT01266096 | PET Imaging of Patients With Melanoma and Malignant Brain Tumors Using an 124I-labeled cRGDY Silica Nanomolecular Particle Tracer: A Microdosing Study | active not recruiting | N/A | 10 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT05307289 | Study of Alterations in Tumor Metabolism Associated With the Development of Immunotherapy Resistance in Melanoma(MEL-META) | recruiting | N/A | 20 | Centre Hospitalier Universitaire de NiceOTHER | 1 | Dec 31, 2025 | clinicaltrials |
| NCT07310758 | Contrast-enhanced Ultrasound for Sentinel Node Detection | recruiting | Phase 2 / Phase 3 | 91 | The Netherlands Cancer InstituteOTHER | 1 | Dec 30, 2025 | clinicaltrials |
| NCT06022029 | A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas.(ON-5001) | recruiting | Phase 1 | 168 | OncoNano Medicine, Inc.INDUSTRY | 2 | Dec 24, 2025 | clinicaltrials |
| NCT07302607 | Predictive Factors of Complete Response to Immunotherapy in Metastatic Melanoma: a Single-center Retrospective Study Between 2013 and 2021(IMM) | recruiting | — | 221 | University Hospital, Strasbourg, FranceOTHER | 1 | Dec 24, 2025 | clinicaltrials |
| NCT03161431 | SX-682 Treatment in Subjects With Metastatic Melanoma Concurrently Treated With Pembrolizumab | active not recruiting | Phase 1 | 77 | Syntrix Biosystems, Inc.INDUSTRY | 1 | Dec 23, 2025 | clinicaltrials |
| NCT04079166 | SCIB1 and iSCIB1+ in Melanoma Patients Receiving Nivolumab With Ipilimumab or SCIB1 With Pembrolizumab (The SCOPE Study) | active not recruiting | Phase 2 | 173 | Scancell LtdINDUSTRY | 1 | Dec 19, 2025 | clinicaltrials |
| NCT06994208 | Characteristics of Adult Patients With Melanoma Diagnosis <40 Years Age.(MELA_2025) | recruiting | — | 25 | Ente Ospedaliero Ospedali GallieraOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07293598 | Investigation of the ROle of faT and inflAmmaTory Cells in mElanoma(ROTATE) | not yet recruiting | — | 20 | The Christie NHS Foundation TrustOTHER | 1 | Dec 19, 2025 | clinicaltrials |
| NCT07251335 | Melanoma of the Skin and Exposure to Solar Ultraviolet Radiation at Work in Modena Territory: a Case-control Study to Promote an Active Search and Prevention of Occupational Diseases Based on Recent INAIL Criteria(Mesur) | recruiting | — | 300 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 18, 2025 | clinicaltrials |
| NCT03567889 | Efficacy of Daromun Neoadjuvant Intratumoral Treatment in Clinical Stage IIIB/C/D Melanoma Patients(NeoDREAM) | recruiting | Phase 3 | 186 | Philogen S.p.A.INDUSTRY | 3 | Dec 17, 2025 | clinicaltrials |
| NCT06794775 | SWE-NEO: Swedish NeoAdjuvant Trial Comparing Monotherapy to Combined Immunotherapy in Resectable Stage III Melanoma(SWE-NEO) | recruiting | Phase 3 | 128 | Hildur HelgadottirOTHER | 1 | Dec 12, 2025 | clinicaltrials |
| NCT05098184 | A Study of GC101 TIL in Advanced Melanoma (10hospital) | recruiting | Early Phase 1 | 50 | Shanghai Juncell TherapeuticsINDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07277920 | Reflectance Confocal Microscopy and Molecular Correlation in Atypical Melanocytic Lesions | recruiting | — | 200 | University of Modena and Reggio EmiliaOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT02374242 | Anti-PD 1 Brain Collaboration for Patients With Melanoma Brain Metastases(ABC) | active not recruiting | Phase 2 | 76 | Melanoma Institute AustraliaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT02307630 | PET Imaging of Solid Tumors Using 124I-Humanized 3F8: A Pilot Study | active not recruiting | N/A | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT06121180 | Study of Cemiplimab Plus Ziv-Aflibercept for Subjects With Metastatic Uveal Melanoma | recruiting | Phase 2 | 32 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT06194929 | Defactinib and Avutometinib, With or Without Encorafenib, for the Treatment of Patients With Brain Metastases From Cutaneous Melanoma(DETERMINE) | recruiting | Phase 1 / Phase 2 | 33 | University of UtahOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07070518 | Study of GV20-0251 in Participants With Solid Tumor Malignancies | recruiting | Phase 1 / Phase 2 | 350 | GV20 TherapeuticsINDUSTRY | 1 | Dec 3, 2025 | clinicaltrials |
| NCT07260591 | VSV-02 Compassionate Use in Advanced Solid Tumors | recruiting | Phase 1 | 6 | The First Affiliated Hospital of Xinxiang Medical CollegeOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT07136181 | Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma(NBM-BMX-UM) | recruiting | Phase 1 / Phase 2 | 36 | Novelwise Pharmaceutical CorporationINDUSTRY | 1 | Nov 28, 2025 | clinicaltrials |
| NCT07252661 | Study of ACC-1898 in Adult Participants With Advanced Solid Tumors | not yet recruiting | Phase 1 | 40 | AccSalus Biosciences, Inc.INDUSTRY | 0 | Nov 28, 2025 | clinicaltrials |
| NCT06508775 | Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies(LONGSAFE) | recruiting | N/A | 40 | Miltenyi Biomedicine GmbHINDUSTRY | 1 | Nov 26, 2025 | clinicaltrials |
| NCT07223411 | Opdualag vs. Cemiplimab/Fianlimab in Relation to the Immunological Response in Tumor and Peripheral Blood in Unresectable or Metastatic Melanoma | recruiting | — | 20 | John KirkwoodOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05768178 | DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770102 | DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT05770544 | DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers.(DETERMINE) | recruiting | Phase 2 / Phase 3 | 30 | Cancer Research UKOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT06332755 | Study to Evaluate LB-LR1109, Administered Alone for the Treatment of Solid Tumor and in Combination With Atezolizumab for the Treatment of NSCLC(LB-LR1109) | recruiting | Phase 1 | 76 | LG ChemINDUSTRY | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07106827 | A Study of GV20-0251 in Advanced or Refractory Solid Tumors | recruiting | Phase 1 | 10 | West China HospitalOTHER | 1 | Nov 24, 2025 | clinicaltrials |
| NCT07246759 | Neutrophil Biomarker Test for Predicting Clinical Benefit From Immunotherapy Based on Flow Cytometry Analysis(NEUTROFLOW) | not yet recruiting | — | 600 | OncoHost Ltd.INDUSTRY | 3 | Nov 24, 2025 | clinicaltrials |
| NCT05238883 | A Study of HFB200301 as a Single Agent and in Combination With Tislelizumab in Adult Patients With Advanced Solid Tumors | active not recruiting | Phase 1 | 72 | HiFiBiO TherapeuticsINDUSTRY | 2 | Nov 21, 2025 | clinicaltrials |
| NCT04196452 | A Retrospective Observational Study on the Long-term Effects of Ipilimumab-treated Pediatric Participants in the Dutch Melanoma Treatment Registry (DMTR) | active not recruiting | — | 10 | Bristol-Myers SquibbINDUSTRY | 0 | Nov 20, 2025 | clinicaltrials |
| NCT06472661 | FUSA With Intratumoral PolyICLC in Regionally Advanced Resectable Melanoma(Mel 70) | recruiting | Early Phase 1 | 11 | University of VirginiaOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT06784648 | Different Doses of BI-1607 in Combination With Pembrolizumab and Ipilimumab, in Participants With Unresectable or Metastatic Melanoma | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 3 | Nov 19, 2025 | clinicaltrials |
| NCT07236528 | Combination of Carilizumab, Apatinib, and Radiotherapy for Advanced Mucosal Melanoma | not yet recruiting | Phase 2 | 30 | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical SchoolOTHER | 0 | Nov 19, 2025 | clinicaltrials |
| NCT07237100 | Mirdametinib in Patients With Advanced NF1-mutant Melanoma | recruiting | Phase 2 | 10 | Kevin Kim, MDOTHER | 1 | Nov 19, 2025 | clinicaltrials |
| NCT05429138 | Ovarian Reserve and Semen Parameters Evolution During Adjuvant Therapy in Melanoma(MELpreserv) | recruiting | — | 80 | Assistance Publique Hopitaux De MarseilleOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT05812027 | A Screening Study to Collect Samples for TAA, HLA & HLA Loss of Heterozygosity in Patients With Metastatic Solid Tumors | active not recruiting | — | 1,150 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT05973487 | A Basket Study of Customized Autologous TCR-T Cell Therapies in Patients With Locally Advanced (Unresectable) or Metastatic Solid Tumors | active not recruiting | Phase 1 | 840 | TScan Therapeutics, Inc.INDUSTRY | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06206707 | FMT in Checkpoint Inhibitor-mediated Diarrhea and Colitis(Immunobiome) | recruiting | N/A | 20 | University of AarhusOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT07155317 | Time-of-Day Specified Immunotherapy for Advanced Melanoma, The TIME Trial | recruiting | Phase 2 | 99 | Emory UniversityOTHER | 1 | Nov 12, 2025 | clinicaltrials |
Data updated 24 days agoSource updated Jan 8, 2026source: clinicaltrials